All In Biotech

Drug Trial Radar · NCT06862453

Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve Adults

Safety, Tolerability and Efficacy Against Controlled Human Malaria Infection of PfSPZ-LARC2 Vaccine in Malaria-naïve Adults

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

42

Planned (sponsor's estimate)

Start

Mar 12, 2026

Primary completion

Aug 30, 2027

Study completion Dec 30, 2027

Sponsor

Lead sponsor
Sanaria Inc.Industry
Sponsor type
Industry
Collaborators
University Hospital Tuebingen; UCLA David Geffen School of Medicine and Fielding School of Public Health; Stanford University; Leiden University
First posted
Mar 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled Phase 1 trial of Plasmodium falciparum (Pf) sporozoite (SPZ) late-arresting replication-competent (LARC) malaria vaccine (PfSPZ-LARC2 Vaccine) administered to healthy, malaria-naive study participants in Germany by direct venous inoculation (DVI) to determine safety, tolerability, and vaccine efficacy (VE) against controlled human malaria infection (CHMI). PfSPZ-LARC2 Vaccine contains a deletion of two genes, the Mei2 and LINUP genes, and undergoes developmental arrest in the late liver stages without releasing merozoites into the blood stream (blood stage parasites). The primary objective of the study is to assess the safety and tolerability of administration of PfSPZ-LARC2 Vaccine, with special attention to the adequacy of attenuation, in the intention-to-treat (ITT) population.

Conditions

  • Malaria Falciparum

Interventions

  • Normal Saline (Placebo)Other

    The blinded control group of the main cohorts will receive normal saline as placebo, also by DVI.

  • PfSPZ-LARC2 VaccineBiological

    Plasmodium falciparum (Pf) sporozoite (SPZ) late-arresting replication-competent (LARC) malaria vaccine (PfSPZ-LARC2 Vaccine) contains a deletion of two genes, the Mei2 and LINUP genes, and undergoes developmental arrest in the late liver stages without releasing merozoites into the blood stream (blood stage parasites).

  • PfSPZ Challenge (7G8)Biological

    Main cohort participants (verum and placebo) will undergo heterologous CHMI using DVI of 3.2x10\^3 PfSPZ of PfSPZ Challenge (7G8), which are infectious cryopreserved Pf sporozoites.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of administration of PfSPZ-LARC2 Vaccine, with special attention to the adequacy of attenuation, in the intention-to-treat (ITT) population: infectionTime frame: 28 days after immunization
  2. Safety and tolerability of administration of PfSPZ-LARC2 Vaccine, with special attention to the adequacy of attenuation, in the intention-to-treat (ITT) population: related AEsTime frame: 7 days after injection of PfSPZ-LARC2 Vaccine
  3. Safety and tolerability of administration of PfSPZ-LARC2 Vaccine, with special attention to the adequacy of attenuation, in the intention-to-treat (ITT) population: related SAEsTime frame: Time of first immunization to the end of the study

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Tubingen

    Tübingen, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.